Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 14,444 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard-of-Care Clear all
Not yet recruiting Not applicable Interventional

Combining Social Network Strategies and Routine Substance Use Screening

NCT07414459
View directory record Official record
Conditions
HIV, Substance Use Disorder (SUD)
Interventions
Substance use disorder screening, Social network intervention
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 16, 2026, 10:05 PM EDT
Recruiting Phase 3 Interventional

Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting

NCT06223269
View directory record Official record
Conditions
Burns Degree Third, Burn (Disorder), Burn Degree Second, Thermal Burn, Wound Heal
Interventions
Skin Xenotransplant, Autograft(ing)
Drug · Procedure
Lead sponsor
XenoTherapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Phoenix, Arizona • Augusta, Georgia • Portland, Maine + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 16, 2026, 10:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

NCT03092323
View directory record Official record
Conditions
Soft Tissue Sarcoma of the Extremity
Interventions
Pembrolizumab
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
12 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Jacksonville, Florida • Iowa City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer

NCT02258659
View directory record Official record
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, radiation therapy, paclitaxel, fluorouracil, hydroxyurea, cisplatin, laboratory biomarker analysis, quality-of-life assessment
Drug · Radiation · Other + 1 more
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Study of Sargramostim in Patients With COVID-19

NCT04411680
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Sargramostim, Standard of care
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Fullerton, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 16, 2026, 10:05 PM EDT
Available No phase listed Expanded access

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

NCT05795361
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Idursulfase-IT
Drug
Lead sponsor
Takeda
Industry
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Phoenix, Arizona • Oakland, California • Wilmington, Delaware + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

NCT02473042
View directory record Official record
Conditions
Post-Operative Nausea and Vomiting, Breast Cancer
Interventions
Electrical Stimulation, Zofran, Dexamethasone, Phenergan, Pepcid, Questionnaire
Procedure · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 16, 2026, 10:05 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

NCT03775486
View directory record Official record
Conditions
Non-small Cell Lung Cancer NSCLC
Interventions
Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 16, 2026, 10:05 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Specular Microscopy Study

NCT02478970
View directory record Official record
Conditions
Endotheliopathies
Interventions
Konan SP4000, NIDEK CEM-350
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 16, 2026, 10:05 PM EDT
Recruiting Phase 2Phase 3 Interventional

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670
View directory record Official record
Conditions
Prostate Cancer
Interventions
Investigators choice of SoC, AAA817
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
35
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1

NCT00735969
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Peginterferon, Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 16, 2026, 10:05 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Acute Partial Thickness Burn Study Comparing Transforming Powder Dressing to Standard of Care Dressing

NCT05424354
View directory record Official record
Conditions
Wounds and Injuries
Interventions
Altrazeal (R) Transforming Powder Dressing, Standard of Care burn dressing
Device · Other
Lead sponsor
ULURU Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
6
States / cities
Orange, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 16, 2026, 10:05 PM EDT
Terminated Phase 1 Interventional Results available

Piloting Acute Care to Primary Care Linkage of Safety Net Patients

NCT01347541
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Cognitive Behavioral Therapy, Motivational Interviewing, FDA-Approved Anti-Anxiety Medications, Standard Care Control
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 16, 2026, 10:05 PM EDT
Withdrawn Phase 2 Interventional

UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia

NCT07001254
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Romiplostim, Immunosuppressive therapy (IST)
Drug
Lead sponsor
Anjali Sharathkumar
Other
Eligibility
2 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 10:05 PM EDT
Terminated Phase 3 Interventional Results available

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

NCT02952586
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Avelumab, Chemoradiation
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
139
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 91 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 16, 2026, 10:05 PM EDT
Terminated No phase listed Observational

Structuring the Integration of Care Management Services For Medicaid Enrollees Recipients With Chronic Illness, Substance Abuse Problems and Possible Psychiatric Disorders

NCT00399373
View directory record Official record
Conditions
Chronic Illness
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Green Sun Medical Dynamic Scoliosis Brace

NCT03641469
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Green Sun Dynamic Brace
Device
Lead sponsor
Green Sun medical
Industry
Eligibility
10 Years to 15 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 16, 2026, 10:05 PM EDT
Not listed No phase listed Observational

MyoVista wavECG Clinical Validation Study Versus Low e' on Echocardiogram

NCT04804969
View directory record Official record
Conditions
Cardiac Disease
Interventions
MyoVista wavECG Test
Device
Lead sponsor
Heart Test Laboratories, Inc.
Industry
Eligibility
22 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
La Jolla, California • Boston, Massachusetts • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NVAMD Satellite Study

NCT02251366
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Physician-guided diagnostic
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Bel Air, Maryland • Bethesda, Maryland • Columbia, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 16, 2026, 10:05 PM EDT
Recruiting No phase listed Observational

A Study of Paramedic HF Management

NCT06874556
View directory record Official record
Conditions
Heart Failure
Interventions
CP-HF Management
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 16, 2026, 10:05 PM EDT
Recruiting Phase 4 Interventional

Frozen Shoulder and Hormone Replacement Therapy

NCT07278323
View directory record Official record
Conditions
Adhesive Capsulitis of the Shoulder, Frozen Shoulder
Interventions
Hormone Replacement Therapy (HRT), Corticosteroid and 1%lidocain, physical therapy
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy

NCT05022641
View directory record Official record
Conditions
Parathyroid Adenoma, Parathyroid Neoplasms, Parathyroid Cancer, Hypercalcemia, Primary Hyperparathyroidism
Interventions
PTeye, Standard of Care
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 16, 2026, 10:05 PM EDT
Not yet recruiting Phase 1 Interventional

Amnion Membrane Powder Mohs Study

NCT07680023
View directory record Official record
Conditions
Wound Heal
Interventions
Amnion Membrane Powder, Standard of Care
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 16, 2026, 10:05 PM EDT
Terminated No phase listed Observational

Influence of Contrast Injection Force on the Accuracy of Vessel Measurements in Cerebral Angiography

NCT03949023
View directory record Official record
Conditions
Cerebral Angiogram
Interventions
Standard of Care Cerebral Angiogram Group
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 16, 2026, 10:05 PM EDT